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Influenza virus non-structural protein 1 (NS1) is the centrepiece of the viral response to the host
interferon (IFN) system. NS1 has been demonstrated previously to be a potential therapeutic
target for antiviral therapy by identification of specific small-molecule inhibitors. This study
demonstrated the biological mechanism for a potent new NS1 antagonist. Compound JJ3297
inhibited virus replication by more than three orders of magnitude without affecting cell viability.
Importantly, it efficiently reversed NS1-induced inhibition of IFN mRNA production. The
hypothesis was tested that JJ3297 facilitates IFN production in infected cells, leading to
protection of the surrounding uninfected cells. Accordingly, the compound efficiently prevented
virus spread through a cell population during a 48 h multi-cycle infection initiated at a very low
m.o.i. Consistent with the hypothesis, the compound had no detectable influence on a 6 h single-
cycle infection initiated at a high m.o.i. The effect of JJ3297 on virus replication was not caused by
inhibition of NS1 expression or its mislocalization in the cell. JJ3297 facilitated the induction of an
IFN-like antiviral state, resulting in increased resistance to subsequent challenge with vesicular
stomatitis virus. The activity of JJ3297 absolutely required the function of cellular RNase L,
indicating that an intact IFN system is required for function of the compound. These results
support a model in which inhibition of NS1 function results in restoration of the IFN-induced
antiviral state and inhibition of virus replication and spread. This represents a new direction for
anti-influenza virus drug development that exploits the IFN pathway to challenge virus replication.
INTRODUCTION
Influenza continues to be a significant global public health
problem, with 3–5 million severe cases annually, including
250000–500000 deaths worldwide (WHO, 2009). The
seasonal vaccination programme remains vulnerable to
antigenic drift. In addition, newly emergent strains
periodically cause pandemics of unpredictable con-
sequence, including the recent swine H1N1 pandemic
(Garten et al., 2009; Jain et al., 2009; Pekosz & Glass, 2008;
Reid et al., 2001; Taubenberger et al., 2001).
High mutation rates among circulating strains cause
problems not only with vaccine efficacy but also with
antiviral therapeutics. Currently, there is only one class of
drug used for treatment of influenza in the USA, the
neuraminidase inhibitors such as oseltamivir. However,
98% of seasonal A/H1N1 strains in North America in 2009
were resistant to oseltamivir (Layne et al., 2009). Therefore,
considering the uncertainty of seasonal vaccine efficacy, the
potential for drug resistance to neuraminidase inhibitors
and the continuing threat of severe pandemics, the
development of novel antivirals is imperative.
We have identified non-structural protein 1 (NS1) as a
candidate target for drug development (Basu et al., 2009).
NS1 satisfies an important requirement for a viable drug
target by being involved in several processes that are crucial
for successful virus replication and propagation (Hale
et al., 2008). Genetic analyses of NS1 have shown that virus
replication, spread and pathogenesis are highly dependent
on the function of this protein (Basler & Aguilar, 2008;
Basler et al., 2001; Bu ¨rger et al., 1985; Donelan et al., 2003;
Egorov et al., 1998; Falco ´n et al., 2005; Garaigorta et al.,
2005; Garcı ´a-Sastre et al., 1998; Hatada et al., 1990; Jackson
et al., 2008; Kochs et al., 2007b; Koennecke et al., 1981;
Ludwig et al., 1995; Shimizu et al., 1983; Talon et al., 2000;
Wolstenholme et al., 1980). Among the key features of NS1
is its capacity for RNA binding, including to dsRNA (Chien
et al., 2004; Donelan et al., 2003; Hatada & Fukuda, 1992;
Hatada et al., 1992, 1997; Lu et al., 1995; Qian et al., 1995;
Qiu & Krug, 1994; Qiu et al., 1995; Wang et al., 1999). One
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and sequester viral dsRNAs from detection by 29-59
oligo(A) synthetase (OAS), a cellular sensor of viral
infection (Min & Krug, 2006). Activated OAS synthesizes
29-59 oligoadenylates, which in turn stimulate latent RNase
L, leading to viral RNA degradation (Silverman, 2007a, b).
NS1 also binds and inhibits the activity of protein kinase R
(PKR), inhibiting the PKR-dependent phosphorylation of
eIF-2a and thereby avoiding shutdown of viral protein
synthesis by PKR (Li et al., 2006; Lu et al., 1995; Min et al.,
2007). Other important roles of NS1 include binding to the
30 kDa subunit of cleavage and polyadenylation specificity
factor (CPSF30), and also to poly(A)-binding protein II
(PABPII) (Chen et al., 1999; Kochs et al., 2007a; Krug et al.,
2003; Kuo & Krug, 2009; Nemeroff et al., 1998; Noah et al.,
2003; Twu et al., 2007). These activities lead to inhibition
of 39-end processing of cellular pre-mRNAs and prevention
of their nuclear export, including interferon (IFN) mRNAs
synthesized in response to viral infection. Further inhibi-
tion of cellular mRNA export is achieved by the interaction
of NS1 with components of the nuclear pore complex
(Satterly et al., 2007). Finally, NS1 has recently been shown
to interact directly with TRIM25, an E3 ubiquitin ligase
responsible for activation of retinoic acid-inducible gene I
(RIG-I), which normally leads to downstream signalling
and stimulation of the IFN response (Guo et al., 2007;
Ludwig & Wolff, 2009; Mibayashi et al., 2007; Pichlmair
et al., 2006). NS1 binds to TRIM25, inhibits RIG-I
ubiquitination and thus prevents the synthesis of cellular
IFN (Gack et al., 2009).
We have previously described four inhibitors of influenza
replication that act by specific inhibition of NS1 function
(Basu et al., 2009). These were identified from a chemical
library based on their ability to suppress the slow-growth
phenotype of budding yeast expressing NS1 protein. Here,
we report a potent novel NS1 inhibitor with some chemical
features retained from one of the original four NS1
antagonists. We demonstrate that its biological mechanism
of virus inhibition involves prevention of virus spread in cell
culture byestablishmentofanantiviralstatethat dependson
RNase L, a major component of the IFN system.
RESULTS
Inhibition of NS1 function by compound JJ3297
Previously, we described the identification of compound
NSC125044, which specifically inhibits NS1 function in
yeast and mammalian cells and also specifically inhibits
influenza virus replication in cell culture (Basu et al., 2009).
Compound JJ3297 was synthesized based on key structural
features of NSC125044, along with additional chemical
modifications to improve its efficacy. The structure of
JJ3297 is shown in Fig. 1. Its design and synthesis will be
reported elsewhere (J. J. Jablonski, D. Basu, D. A. Engel and
H. M. Geysen, unpublished results). To relate the activity of
JJ3297 to NSC125044, each was used to challenge NS1
function in cells infected with influenza virus. In infected
cells, one important function of NS1 is to block IFN gene
expression (Garcı ´a-Sastre et al., 1998; Hale et al., 2008).
Previously, we demonstrated that treatment of infected cells
with NSC125044 restored IFN-b mRNA expression, con-
sistent with its ability to inhibit NS1 function. To test the
effect of JJ3297 on IFN-b mRNA expression, Madin–Darby
caninekidney (MDCK)cellswereinfectedwithA/PR/8at an
m.o.i. of 2 in the presence or absence of the compound. As
shown in Fig. 2(a) (upper panel), after 6 h of infection and
treatment, JJ3297 strongly restored IFN-b mRNA levels, to a
degree nearly equal to that seen in uninfected cells treated
with poly(I:C). As reported previously for NSC125044,
treatment of cells with JJ3297 alone, in the absence of virus
infection, had no effect on IFN mRNA levels (Fig. 2a, lower
panel), demonstrating that JJ3297 does not act directly to
induceIFNproduction, butratheractsonlyin thecontextof
infection. These data indicated that JJ3297 reverses the
blockade of IFN synthesis that normally occurs in infected
cells due to the action of NS1. Previously, we also reported
that NS1 expression in Saccharomyces cerevisiae triggered a
slow-growth phenotype and that specific inhibition of NS1
function by NSC125044 restored growth of the yeast. As
expected, JJ3297 also restored growth of yeast cells
expressing NS1 (data not shown). These data demonstrated
that JJ3297 and NSC125044 share essential chemical features
leading to the inhibition of NS1 function.
Inhibition of virus replication
To determine the effect of JJ3297 on virus replication, cells
infected at an m.o.i. of 0.1 were treated with increasing
concentrations of the compoundfor 48 h followed by analysis
of the culture supernatants by TCID50 assay. As shown in Fig.
2(b), virus replication was inhibited by approximately three
orders of magnitude over a 10 mM range of concentration.
The 50% effective concentration (EC50) value for JJ3297 was
0.8 mM( n53 experiments, one of which is shown in Fig. 2b).
This represented a more than tenfold improvement in EC50
compared with NSC125044, as reported previously. Fig. 2(c)
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100 mM over a 48 h incubation. The calculated selective index
for JJ3297 was at least 125.
Inhibition of multi-cycle but not single-cycle
replication
The ability of JJ3297 to reverse the inhibition of IFN
mRNA induction by NS1 suggested a straightforward
Fig. 1. Chemical structure of JJ3297.
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We explored the hypothesis that treatment of infected cells
with the compound limits virus replication through
restoration of IFN expression, leading to protection of
surrounding cells. One prediction of this hypothesis is that
JJ3297 would act efficiently in the context of a low-
multiplicity (multi-cycle) infection, in which newly
released IFN could protect surrounding uninfected cells
but would not act in a single-cycle (high m.o.i.) infection
in which 100% of cells are infected prior to the restoration
of IFN synthesis caused by JJ3297.
Accordingly, MDCK cells were infected at an m.o.i. of
either 0.01 (low) or 3 (high) with A/PR/8 in a multi-cycle
infection and incubated in the presence of 5 mM JJ3297 or
1% DMSO. Treatment with the compound was initiated at
the time of infection and samples were collected after 4, 8,
12, 24 and 48 h for determination of TCID50. Fig. 3
illustrates that treatment with JJ3297 had a profound effect
on virus replication in the low-multiplicity infection,
decreasing the amount of virus in the cell supernatant by
approximately 3.5 orders of magnitude. However, the
compound had no effect in cells infected at a high m.o.i.
These data strongly suggested that inhibition of NS1 by
JJ3297 resulted in inhibition of replication and spread
through an IFN-dependent mechanism.
To test whether JJ3297 in fact inhibited virus spread,
immunofluorescence experiments were performed. MDCK
cells were infected at an m.o.i. of 0.01 and incubated in the
presence of 5 mM JJ3297 or 1% DMSO. After 72 h, the
cells were fixed and stained for viral nucleoprotein (NP).
As can be seen in Fig. 4(a), mock-infected cells showed no
NP staining, whereas all cells in the DMSO-treated sample
showed evidence of viral protein expression after 72 h
of infection. By contrast, only a small fraction of cells
expressed NP in the sample treated with JJ3297, dem-
onstrating that the compound efficiently inhibited the
spread of the virus. Fig. 4(b) shows that, in stark contrast,
during a high-multiplicity infection, 100% of the cells
expressed NP whether or not they were treated with JJ3297. Fig. 2. JJ3297-dependent restoration of IFN-b mRNA levels and
inhibition of virus replication in MDCK cells. (a) Upper panel: cells
were mock infected, treated with poly(I:C) or infected with influenza
strain A/PR/8 at an m.o.i. of 2 and treated with increasing
concentrations of JJ3297 as indicated or with 1% DMSO (0 mM).
After 6 h, cells were harvested for RT-PCR analysis of IFN-b and b-
actin mRNA levels. Lower panel: cells were mock infected, treated
with poly(I:C) or infected with influenza A/PR/8 at an m.o.i. of 2 and
treated with either 1% DMSO or 5 mM JJ3297 as indicated. After
6 h, cells were harvested for RT-PCR analysis of IFN-b and b-actin
mRNAs. (b) Triplicate cultures were infected with A/PR/8 at an
m.o.i. of 0.1 and treated with the indicated concentrations of JJ3297
or 1% DMSO (0 mM). After 48 h, the supernatants were collected
and analysed to determine TCID50. (c) Triplicate cultures were
incubated in the presence of JJ3297 at the indicated concentrations
for 48 h. Cells were disrupted with CellTiter Glo reagent according
to manufacturer’s protocol and the luminescent signal was
measured, indicating the extent of cell viability. Fig. 3. Influenza replication in the presence or absence of JJ3297
during multi-cycle infection initiated at a low or high m.o.i. MDCK
cells were infected with A/PR/8 at an m.o.i. of 0.01 (low) or 3
(high) and treated with 5 mM JJ3297 (‘treated’) or 1% DMSO
(‘untreated’). At the indicated time points, the virus titre was
measured by TCID50 analysis.
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infection, in which cells were infected at a high m.o.i. for a
total of 5 h in the absence or presence of JJ3297 (Fig. 4c).
JJ3297 had no effect on the expression of NP as judged by
immunofluorescence microscopy. Western blot analysis of
NP during the first cycle of replication also revealed no
effect of JJ3297 on NP levels, indicating that the
compound’s activity did not affect expression of NP (data
not shown). As also shown in Fig. 4(c), expression of NS1
protein itself was not affected in the single-cycle infection
by treatment with JJ3297, nor was its localization,
indicating that the compound does not act by leading to
degradation of NS1 or grossly disrupting its subcellular
localization.
Induction of a protective antiviral state in
response to JJ3297
We tested for the induction of an antiviral state in infected
cells treated with JJ3297. To do this, cells were first infected
with A/PR/8 at an m.o.i. of 0.01 in the presence of 5 mM
JJ3297 for 48 h. As already shown in Fig. 4(a), this resulted
in the vast majority of cells showing no evidence of
infection. To test for the establishment of an antiviral state,
the culture was then infected with a GFP-expressing
vesicular stomatits virus (VSV) construct. This construct
contained the gene for GFP in place of the native VSV
glycoprotein, VSV-G, and therefore can replicate within
cells but cannot be released from infected cells (Takada
et al., 1997). After overnight incubation in the presence of
VSV–GFP, cells were analysed by fluorescence microscopy.
As shown in Fig. 5(a), JJ3297 treatment of influenza virus-
infected cells resulted in a significant reduction in the
number of cells expressing GFP. As expected, influenza
virus-infected cells treated with DMSO instead of JJ3297
exhibited significant cell loss and overwhelming cytopathic
effect resulting from 48 h of unrestrained virus replication
(data not shown). To quantify the inhibitory effect of
JJ3297 on VSV–GFP replication, the cells were harvested
and evaluated for GFP expression using flow cytometry,
which revealed a twofold reduction in the number of GFP-
positive cells (Fig. 5b). This level of protection was
consistent in four independent experiments, as shown in
Fig. 5(c).
Fig. 4. Inhibition of multi-cycle (low m.o.i.) but not single-cycle (high m.o.i.) infections. (a) MDCK cells were mock infected or
infected with influenza A/PR/8 at an m.o.i. of 0.01 and treated with 1% DMSO or 5 mM JJ3297. After 72 h, the cells were fixed
and stained for NP (upper panels) or DAPI (lower panels). Arrows indicate DAPI-stained cells expressing NP. (b) MDCK cells
were infected at an m.o.i. of 5 and treated as described in (a). (c) MDCK cells were mock infected or infected with A/PR/8 at an
m.o.i. of 5 (NS1 stained) or 10 (NP stained) and treated with 1% DMSO or 5 mM JJ3297. Allowing for a single cycle of
replication, the cells were fixed after 5 h and stained for NS1, NP or DAPI as indicated. Magnification: (a, b) 20; (c) 40 (NP)
and 60 (NS1 and mock).
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MDCK cells were mock infected or infected with A/PR/8 at an
m.o.i. of 0.01 and treated with 5 mM JJ3297. After 48 h, the cells
were infected with VSV–GFP at an m.o.i. of 5, incubated overnight
and visualized live for GFP fluorescence and by phase-contrast
microscopy. (b) Example of data from flow cytometry. Arrows
indicate GFP-positive cells. Mock-infected cells were not infected
with A/PR/8, but were treated with JJ3297 for 48 h, followed by
infection overnight with VSV–GFP. Infected cells were infected
with A/PR/8 for 48 h in the presence of JJ3297, followed by
infection overnight with VSV–GFP. (c) Quantification of data from
quadruplicate experiments as illustrated in (b). Bars represent the
percentage of cells in the population expressing GFP. (d) Wild-
type (WT) MEFs or RNase L
”/” MEFs were mock infected or
infected with A/PR/8 at an m.o.i. of 0.1 and incubated in the
presence of 5 mM JJ3297 or 1% DMSO. After 24 h, supernatants
were harvested and the concentration of IFN-b was determined by
ELISA. Increasing concentrations of IFN-b standards were
included for comparison (left columns). Black horizontal line, IFN-
b level of 15.6 pg ml
”1 which is the lower limit of detection for the
ELISA assay. (e) MEFs are protected from VSV infection by
recombinant IFN-b. Cells were pre-treated with 100 U mouse
recombinant IFN-b ml
”1 for 6 h (where indicated) and then
infected with VSV–GFP at an m.o.i. of 5. After overnight
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cells treated with JJ3297, a quantitative ELISA was
performed. Mouse embryonic fibroblast (MEF) cells were
mock infected or infected with A/PR/8 at an m.o.i. of 0.1
and treated with DMSO or 5 mM JJ3297. After 24 h, the
medium was collected and assayed for the presence of IFN-
b. Fig. 5(d) shows that only cells that were infected and
treated with JJ3297 produced significant levels of IFN-b,
corresponding to 69 pg ml
21. Fig. 5(e) shows the
sensitivity of the VSV–GFP construct to pre-treatment of
MEF cells with 100 U recombinant murine IFN-b ml
21 for
6 h prior to VSV challenge, revealing a similar level of
inhibition of VSV–GFP replication as was shown in Fig.
5(a). To prove that JJ3297 had no direct effect on VSV–
GFP replication, MDCK cells were infected with the VSV–
GFP construct in the presence or absence of 5 mM JJ3297
for 72 h. A complete lack of effect on VSV–GFP replication
is shown in Fig. 5(f). This also proved that JJ3297 by itself
does not induce an antiviral state. Taken together, these
data demonstrated the presence of IFN-b and the
establishment of an IFN-like antiviral state in influenza
virus-infected cells treated with compound JJ3297.
The activity of JJ3297 requires a functional IFN
response pathway
To conclusively implicate the IFN system in the action of
JJ3297, a genetic experiment was performed to test the
requirement for a functional IFN pathway in the activity of
JJ3297. RNase L is a major downstream effector of IFN
action that has been strongly implicated in the innate
immune response to influenza virus infection, as well as
NS1 activity (Min & Krug, 2006). RNase L is activated in
virus-infected cells by 29-59 oligoadenylates synthesized in
response to IFN and the presence of dsRNA (Silverman,
2007a, b). Therefore, we wondered whether cells lacking
RNase L would be sensitive to compound JJ3297. To test
this, RNase L
2/2 and parental wild-type MEF cells were
infected with A/PR/8-MA (mouse-adapted strain) at an
m.o.i. of 0.1 in the absence or presence of 5 mM JJ3297 for
48 h. As shown in Fig. 6(a), parental MEF cells were readily
infected by A/PR/8-MA, as revealed by immunofluorescent
staining for NP, and there was almost complete inhibition
of virus replication due to JJ3297 treatment. In contrast,
RNase L
2/2 MEF cells were completely resistant to the
action of JJ3297, clearly implicating a functional IFN
system in its mechanism of action (Fig. 6b). Consistent
with this, TCID50 analysis of wild-type and RNase L
2/2
cells infected with A/PR/8-MA in the absence or presence
of JJ3297 also demonstrated that cells lacking RNase L were
Fig. 6. JJ3297 activity depends on a functional IFN response
pathway. (a, b) Parental wild-type (WT) (a) or RNase L
”/” (b) MEFs
were infected with A/PR/8-MA at an m.o.i. of 0.1 and treated with
5 mM JJ3297 or 1% DMSO. After 48 h, the cells were fixed and
stained for NP. DAPI was used to visualize cell nuclei. (c)
Quantification of replication in WT or RNase L
”/” MEFs.
incubation, cells were visualized live for GFP fluorescence and by
phase-contrast microscopy. (f) Uninfected MDCK cells were
incubated in the presence of 1% DMSO or 5 mM JJ3297. After
72 h, the cells were infected with VSV–GFP at an m.o.i. of 0.5,
incubated overnight and visualized live for GFP fluorescence and
by phase-contrast microscopy.
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difference in the overall virus titre between the parental and
RNase L
2/2 cells at either 24 or 48 h after infection in the
absence of JJ3297 (Fig. 6c, DMSO-treated samples). This
was presumably due to the fact that NS1 efficiently blocked
the IFN system in the parental cells, thereby circumventing
the role of RNase L. Also consistent with these findings, we
observed a complete lack of IFN-b induction in the RNase
L
2/2 cells that were infected with A/PR/8 and treated with
JJ3297 (Fig. 5d). These data confirmed that compound
JJ3297 inhibits influenza replication in a manner that
requires an intact IFN system.
Lack of effect of JJ3297 on NS1 binding to dsRNA
in vitro
To explore a possible mechanism of JJ3297 action, the
compound was used to challenge an in vitro binding assay
for NS1–dsRNA interactions. Bacterially expressed full-
length NS1 from A/PR/8 was bound to agarose beads
containing immobilized poly(I:C). To ensure that binding
of NS1 to the beads was specific, two control experiments
were performed. First, the large C-terminal effector domain
of NS1, which lacks the dsRNA-binding domain, was
incubated with poly(I:C) beads and found not to associate
(Fig. 7, lower panel), whereas full-length NS1 associated
efficiently (Fig. 7, upper panel, control). Next, full-length
NS1 bound to the beads was incubated with a tenfold
excess of free poly(I:C) for 2 h at 4 uC. Under these
conditions, NS1 was efficiently released from the beads,
whereas incubation in binding buffer alone under the same
conditions resulted in no release of bound NS1. Having
demonstrated the specificity of binding, we then incubated
bound NS1 with JJ3297 up to a concentration of 50 mM,
which is 50 times higher than the amount of JJ3297 that
reduced virus replication tenfold (see Fig. 2b). No effect of
JJ3297 on the release of NS1 from the beads was observed
(Fig. 7, top panel), suggesting that the compound does not
target the NS1–dsRNA interaction in its mechanism of
action.
DISCUSSION
We have presented the results of our continuing inves-
tigation of novel NS1 antagonists that could potentially be
used as therapeutics for treatment of influenza in humans.
The precise mechanism of action of JJ3297 remains to be
elucidated. NS1 disrupts several steps required for the IFN
response, and it is likely that at least one of them is affected
by JJ3297, either directly or indirectly. For example, it has
been shown that inhibiting the interaction between NS1
and CPSF30 restores IFN synthesis in infected cells,
establishing this interaction as a potential antiviral target
(Das et al., 2010; Krug & Aramini, 2009; Twu et al., 2006).
NS1 also binds directly to TRIM25 and prevents it from
activating the cellular RNA sensor RIG-I, an important step
in activation of the IFN response (Gack et al., 2009).
Therefore, JJ3297 might act by preventing or disrupting the
TRIM25–NS1 interaction. Another possible function of the
compound that could lead to an increase in IFN
production would be restoration of efficient mRNA export
from the nucleus, which NS1 inhibits by forming a
complex with several members of the export machinery
(Satterly et al., 2007).
As shown in Fig. 7, we saw no evidence for a direct effect of
JJ3297 on in vitro binding of NS1 to dsRNA. This suggests
that the main mechanism of JJ3297 is not to disrupt or
prevent dsRNA binding to NS1 in the cell. However, as
JJ3297 may act indirectly to perturb NS1 activity, it is
possible that this could result in a change in the dsRNA
association with NS1 in the cell, leading to downstream
effects on both IFN production and activity (e.g. by an
effect on RNase L activation, which depends on dsRNA
through the action of the OAS). Consistent with all of the
above mechanisms, we observed that the effect of JJ3297 on
virus replication depended strictly on the presence of
RNase L. As a major effector of IFN-dependent anti-
influenza activity, the loss of RNase L in the knockout cell
line removes a downstream step in the IFN pathway into
which all of the above mechanisms could feed. In addition,
RNase L is required for maximal IFN expression in
response to poly(I:C) or Sendai virus infection, and also
mediates amplification of induction of IFN gene transcrip-
tion through the generation of cleaved viral RNAs that
activate the IFN response (Malathi et al., 2007). Our
observation that IFN induction was undetectable in RNase
L
2/2 MEF cells infected with A/PR/8 and treated with
JJ3297 is in line with this possibility. These effects in
combination probably account for our observation that
Fig. 7. Lack of effect of JJ3297 on NS1 binding to dsRNA in vitro.
Upper panel: recombinant NS1 (A/PR/8) was bound to poly(I:C)
immobilized on agarose beads and challenged with control buffer
(lanes 1 and 2), a tenfold excess of free poly(I:C) (lanes 3 and 4),
0.025% DMSO (lanes 5 and 6) or 50 mM JJ3297 (lanes 7 and 8).
Reactions were incubated for 2 h at 4 6C and the pellet (P) and
supernatant (S) fractions were analysed by PAGE and Western
blotting for NS1. Lower panel: NS1 C-terminal effector domain
was incubated with poly(I:C) immobilized on agarose beads and
analysed as described above.
Supernatants from cells infected with A/PR/8-MA at a low m.o.i.
and treated with 5 mM JJ3297 or 1% DMSO were harvested at 24
and 48 h time points and the virus titre was assayed for samples
from three independent cultures by TCID50 determination.
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2/2 MEF cells are completely resistant to JJ3297
treatment. Therefore, the observed dependence of JJ3297
activity on RNase L does not necessarily imply a role of
RNase L in the direct mechanism of JJ3297; rather, it
demonstrates the role of the IFN pathway in this
mechanism. For instance, it is likely that knockout cells
for other IFN pathway components such as RIG-I would
also be insensitive to the action of JJ3297. It will be
interesting to determine the exact mode of inhibition of
NS1 by JJ3297, and experiments addressing this issue are
under way.
An important criterion for an effective viral target protein
is that virus replication and/or spread is highly dependent
on the function of the protein. This has been demonstrated
for NS1 both in cell culture and in animal model systems
(Basler & Aguilar, 2008; Basler et al., 2001; Bu ¨rger et al.,
1985; Donelan et al., 2003; Egorov et al., 1998; Falco ´n et al.,
2005; Garaigorta et al., 2005; Garcı ´a-Sastre et al., 1998;
Hatada et al., 1990; Jackson et al., 2008; Kochs et al., 2007b;
Koennecke et al., 1981; Ludwig et al., 1995; Shimizu et al.,
1983; Talon et al., 2000; Wolstenholme et al., 1980). In
particular, ongoing efforts to develop more effective
influenza vaccines include the use of live-attenuated strains
that contain deleted or truncated forms of NS1 (Palese,
2006; Palese & Garcı ´a-Sastre, 2002; Schickli et al., 2001;
Solo ´rzano et al., 2005). Infections of immunocompetent
hosts with these viruses result in establishment of
protective immunity against future challenge without
causing any significant adverse effects (Baskin et al.,
2007; Chambers et al., 2009; Hai et al., 2008; Mueller
et al., 2010; Richt et al., 2006; Romanova et al., 2009; Talon
et al., 2000; Vincent et al., 2007; Wacheck et al., 2010;
Wressnigg et al., 2009a, b). The usefulness of these strains
as potential vaccine candidates is illustrated by their highly
attenuated growth in animals. Therefore, it is likely that a
drug that blocks all or part of the multiple functions of NS1
may act efficiently to limit infection in the host. In
addition, activation of the IFN system in drug-treated
animals or humans might be expected to aid in the
establishment of the immune response and clearing the
virus from the body (Bracci et al., 2005; Le Bon et al., 2001;
Palese, 2006; Proietti et al., 2002; Talon et al., 2000; Tovey
et al., 2008). This aspect of JJ3297 activity will be addressed
in future animal studies.
Based on the results presented here, we propose the
following explanation: (i) when cells are infected with
influenza virus at a low m.o.i. in the absence of treatment
with JJ3297, NS1 protein effectively inhibits the synthesis of
IFN, allowing the replicated virus to spread through the cell
population, resulting in a high virus titre in the medium;
(ii) treatment with JJ3297 during infection at low
multiplicity allows the infected cells to synthesize IFN
despite the presence of NS1, leading to induction of an
antiviral state in neighbouring uninfected cells and
inhibition of virus spread, also resulting in a lowered virus
titre in the medium; (iii) treatment with JJ3297 during
infection at high multiplicity also leads to the restoration of
IFN synthesis in infected cells, but because the compound
was found not to interfere with single-cycle infection, and
as the virus initially infected the vast majority of cells in the
population, no effect on virus spread or medium titre was
observed.
METHODS
Cells and viruses. MDCK cells were grown as monolayers in Iscove’s
modified Dulbecco’s medium with 10% FBS, 2 mM L-glutamine and
antibiotics. Parental and RNase L
2/2 MEFs, gifts from Robert
Silverman (Malathi et al., 2007), were maintained in Dulbecco’s
modified Eagle’s medium with 10% FBS and antibiotics. Media and
sera were from Invitrogen. Viral dilutions and infections were in
medium supplemented with 0.3% BSA, 0.22% sodium bicarbonate
and 0.25 U TPCK-treated trypsin (Invitrogen) ml
21. All compound
treatments were initiated at the time of infection. Some cultures were
incubated with 100 U recombinant mouse IFN-b (Millipore) ml
21
for 6 h prior to infection. Influenza viruses A/PR/8/34 and its mouse-
adapted variant (A/PR/8-MA) were gifts from Thomas Braciale,
Department of Pathology, University of Virginia, USA. VSV–GFP was
a gift from Judith White (Takada et al., 1997).
Virus replication assays. Cell monolayers were infected at an m.o.i.
of 0.1 for 48 h in the presence or absence of the compound, which
was added at the beginning of infection. Virus titres were determined
by TCID50 analysis (Reed & Muench, 1938).
Cell viability assay. Opaque-walled 96-well plates were seeded with
10
4 MDCK cells per well in 100 ml medium and incubated overnight
at 37 uC. The compound was added to triplicate wells for each
concentration tested and incubated for 48 h at 37 uC. The plate was
equilibrated for 30 min at room temperature and 100 ml CellTiter Glo
reagent (Promega) added according to the manufacturer’s protocol.
The plate was shaken for 2 min and then incubated for 10 min at
room temperature. Luminescence was recorded in an LMAX 384
reader (Molecular Devices) with integration time of 1 s.
RT-PCR. MDCK cells were infected for 6 h with A/PR/8 at an m.o.i.
of 2.0, and total RNA was isolated using RNeasy (Qiagen). Total RNA
(2 mg) was incubated with random nanomers (New England Biolabs)
at a final concentration of 2 mM. Reverse transcription was with 10 U
Moloney murine leukemia virus reverse transcriptase ml
21 (New
England Biolabs) in the presence of 1 U RNase inhibitor ml
21 (New
England Biolabs). Thereafter, 1/20 vol. cDNA was used as the
template for PCR amplification (30 cycles of 94 uC for 30 s, 55 uC for
20 s, 72 uC for 30 s). The following primer pairs were used: canine
IFN-b (GenBank accession no. NM_001135787), 59-CCAGTTCC-
AGAAGGAGGACA-39 and 59-CCTGTTGTCCCAGGTGAAGT-39;a n d
canine b-actin (GenBank accession no. XM_536230), 59-GGCATC-
CTGACCCTGAAGTA-39 and 59-GGGGTGTTGAAAGTCTCGAA-39.
Immunofluorescence. MDCK cells were grown on coverslips
(Fisher) for 24 h prior to infection. Infected cells were washed with
PBS and fixed by incubation in fresh 4% paraformaldehyde in PBS
for 20 min at room temperature. The fixative was removed and the
cells were permeabilized by incubating with pre-chilled 0.5% Triton
X-100 in PBS for 10 min at 4 uC. All subsequent steps were
performed at room temperature. The cells were then washed in PBS
for three 15 min washes. Staining was performed according to a
protocol described previously (Ornelles & Shenk, 1991). First, cells
were incubated in blocking buffer [25 mM Tris/HCl (pH 8.0),
137 mM NaCl, 3 mM KCl, 1.5 mM MgCl2, 2.5% BSA, 13 mM
glycine, 0.05% Tween 20 and 20% goat serum] by placing the
coverslips face down on a 100 ml drop of buffer in a humidified
Influenza NS1 inhibitor requires RNase L
http://vir.sgmjournals.org 67chamber for 1 h. Next, cells were placed on a 100 ml drop of anti-NP
mouse mAb (Centers for Disease Control and Prevention) diluted
1:1000 in blocking buffer and incubated for 100 min. After six 10 min
washes in PBS supplemented with 0.1% Tween 20, the coverslips were
placed face down on a 100 ml drop of a 1:2000 dilution (in blocking
buffer) of goat anti-mouse secondary antibody conjugated to Alexa 488
(Invitrogen) for 45 min. Following this incubation, the cells were
washed six times for 10 min each in PBS supplemented with 0.1%
Tween 20 and twice for 5 min each in unsupplemented PBS. Finally,
the cells were mounted on glass slides in Vectashield mounting media
with DAPI (Vector Laboratories). NS1 visualization was performed
identically, except that the antibodies used were anti-NS1 H1N1 rabbit
polyclonal antibody (diluted 1:400 in blocking buffer; a gift from Peter
Palese, Department of Microbiology, Mount Sinai School of Medicine)
and goat anti-rabbit secondary antibody conjugated to Alexa 594
(diluted 1:2000 in blocking buffer; Invitrogen). Slides were sealed with
nail polish and examined using a Nikon Eclipse E800 fluorescence
microscope and a Princeton Instruments charged-coupled-device
camera. Expression of GFP in live cells was examined using a Nikon
Eclipse TE2000-E fluorescence inverted microscope and a Hamamatsu
ORCA-ER digital camera (Improvision Open Lab software).
Flow cytometry. Infected cells were trypsinized, collected into 1.5 ml
tubes, washed with PBS and fixed by resuspending in fresh 2%
paraformaldehyde in PBS for 10 min. Fixed cells were pelleted
(2 min, 300 g), washed with PBS and analysed using a Becton
Dickinson FACSCalibur Benchtop Analyser. After isolating the cell
population from debris and aggregates using forward and side scatter,
the fraction of GFP-positive cells was determined. The threshold for
GFP detection was established using a control cell population that was
not infected with VSV–GFP.
dsRNA-binding assay. Recombinant His-tagged NS1 (A/PR/8) or
the NS1 C-terminal ‘effector’ domain were purified from Eshcerichia
coli using Ni
2+ beads. Poly(I:C)-coated agarose beads were prepared
from poly(C)-coated beads (Sigma) by incubating them with 2 vols
poly(I) (2 mg ml
21; Sigma) in 50 mM Tris/HCl (pH 7.0) and
150 mM NaCl overnight at 4 uC. After washing in the same buffer,
20 ml of a 50% slurry of bead-bound poly(I:C) was incubated with
50 ng NS1 in binding buffer [50 mM Tris/HCl (pH 7.5), 150 mM
NaCl, 1 mM EDTA and 1% NP-40] in a total volume of 40 ml for 2 h
at 4 uC. The beads were washed three times with binding buffer,
mixed with reagents identified in the legend to Fig. 7 and incubated
for 2 h at 4 uC. The bead fraction and supernatants were separated by
PAGE and analysed by Western blotting using polyclonal anti-NS1
antibody (1:2000).
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